TY - JOUR AU - Amin, Mohammad Feroz AU - Afsana, Faria AU - Shefin, Sultana Marufa AU - Selim, Shahjada AU - Ifhtekhar, Mahboob PY - 2020/12/31 Y2 - 2024/03/29 TI - Dapagliflozin in the management of type 2 diabetes mellitus: a real-life experience in Bangladesh JF - BIRDEM Medical Journal JA - Birdem Med J VL - 11 IS - 1 SE - Original Articles DO - 10.3329/birdem.v11i1.51031 UR - https://www.banglajol.info/index.php/BIRDEM/article/view/51031 SP - 57-62 AB - <p><strong>Background: </strong>Dapagliflozin, a selective renal sodium-glucose cotransporter-2 inhibitor (SGLT2i), lowers plasma glucose by increasing urinary excretion of glucose. This study evaluated the efficacy and safety of dapagliflozin as add on therapy for a selected group of Bangladeshi type 2 diabetic patients.</p><p><strong>Methods: </strong>This was a 24-week, open-label, prospective, real-life study including type 2 diabetic patients with glycated hemoglobin (HbA1c) 7.0–10% (N =53). Study subjects were selectively assigned to dapagliflozin 5 mg once-daily in the morning along with ongoing oral anti-diabetic drug (OAD). The primary end point was to see the safety (adverse events) and efficacy (reduction of fasting and post-prandial blood glucose, HbA1c) of dapagliflozin.</p><p><strong>Results: </strong>Mean HbA1c changes from baseline to week 24 was – 1.15 ± 0.82 % (P = 0.000) and weight reduction was – 2.49 ± 0.32 kg from base line (P=0.000). Among total study subjects, 6 (11.3 %) had developed urinary tract infection (UTI). There were no major episodes of hypoglycemia or renal function deterioration.</p><p><strong>Conclusion: </strong>Dapagliflozin showed significant reduction of HbA1c as add on therapy. The low incidence of hypoglycemia and UTI make dapagliflozin as an acceptable addition to existing treatment option for type 2 diabetes in Bangladeshi population.</p><p>Birdem Med J 2021; 11(1): 57-62</p> ER -